LD Micro: 360 Companies--Set to Present this Week. Citius Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Save for retirement with Webull Traditional, Roth or Rollover IRA. Get daily stock ideas top-performing Wall Street analysts. Earnings Trend: CTXR is unprofitable, and losses have increased over the past 5 years at a rate of 26.9% per year. The official website for Citius Pharmaceuticals is www.citiuspharma.com. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Since then, CTXR shares have increased by 78.3% and is now trading at $1.07. You may vote once every thirty days. When available, Bid and Ask information from the Cboe BZX Exchange is updated as new data is received. at InvestorsObserver.com Wed, Sep. 16. It primarily focuses on developing anti-infective, cancer care, and prescription products. An investor that had 100 shares of Citius Pharmaceuticals stock prior to the reverse split would have 7 shares after the split.
The value of stocks may fluctuate and as a result, clients may lose more than their original investment.Options involve risks and are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Citius Pharmaceuticals (CTXR) Jumps: Stock Rises 5.1%. Live educational sessions using site features to explore today's markets. Get short term trading ideas from the MarketBeat Idea Engine. It primarily focuses on developing anti-infective, cancer care, and prescription products. Shares of CTXR can be purchased through any online brokerage account. Note: The Cboe BZX Exchange currently accounts for approximately 11-12% of all U.S. equity trading each day. Citius Pharmaceuticals has a P/B Ratio of 1.27. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any … Citius Pharmaceuticals does not currently pay a dividend. All Rights Reserved. 08:35AM : Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 8th 2017. Based on an average daily volume of 1,320,000 shares, the days-to-cover ratio is currently 0.6 days. Volume always reflects consolidated markets. Invest in thousands of companies using our trading tools and analytics to create your own financial portfolio. Volume is also updated but is the delayed consolidated Volume from the symbol's exchange. Factset: FactSet Research Systems Inc.2019. © 2020 Webull Financial LLC, All rights reserved. Find real-time CTXR - Citius Pharmaceuticals Inc stock quotes, company profile, news and forecasts from CNN Business. Please log in to your account or sign up in order to add this asset to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist.
Learn about financial terms, types of investments, trading strategies and more. Citius Pharmaceuticals' Mino-Lok® Highly Efficacious in Rapidly Eradicating Candida auris, Citius Pharmaceuticals to Present at the ThinkEquity Conference, Citius Pharmaceuticals Presents Data on Mino-Lok® Showing 98% Clinical Efficacy, MicroCap Review Magazine Spring 2019 Issue Now Available, Citius Pharmaceuticals Inc (CTXR) President and CEO Myron Z Holubiak Bought $200,648 of Shares, Citius Pharmaceuticals Successfully Raises $5.3 Million, Citius Announces $5.3 Million Registered Direct Offering Priced At-the-Market, LD Micro Virtual Conference Is Live, March 12th and 13th, Imagine Owning Citius Pharmaceuticals (NASDAQ:CTXR) And Taking A 97% Loss Square On The Chin, Four Tech Stocks Looking To Test February Highs, Citius Pharmaceuticals to Present at NobleCon15 Investor Conference, Citius Licenses Mino-Wrap From MD Anderson Cancer Center, Citius Pharmaceuticals to Present at Biotech Showcase Investor Conference, Citius Pharmaceuticals Provides Updates on Mino-Lok® and CITI-002, Citius Pharmaceuticals Presentation Now Available for On-Demand Viewing, Live Investor Conference & Webinar: NYSE, NASDAQ, and OTC companies present December 6th, Citius Pharmaceuticals to Present at the 11th Annual LD Micro Main Event, Citius Pharmaceuticals to Webcast, Live, at VirtualInvestorConferences.com December 6, Citius Pharmaceuticals to Present at Dawson James Securities 4th Annual Small Cap Growth Conference, Citius Reports On Activities During Infectious Disease Week 2018, Citius Announces The Publication Of European Patent For Mino-Lok®, Citius Announces The Issuance Of The Patent On The Advanced Stability Of Mino-Lok® By USPTO, Citius Pharmaceuticals Successfully Raises $10 Million, Citius Announces Closing of $10.0 Million Underwritten Offering Priced At-the-Market, Pot Stocks & Biotech Stocks to Watch in 2018 & Beyond, Citius Announces Pricing of $10.0 Million Underwritten Offering Priced At-the-Market, CTRXs Ph3 Mino-Lok Fills Unmet Need for Catheter-Related Blood Infection Antibiotic, Citius Announces The Notice Of Allowance From The USPTO On The Advanced Stability Patent Application For Mino-Lok®, Citius Announces Key Addition to its Scientific Advisory Board, Citius Provides Clinical Update And Progress Of The Mino-Lok® Phase 3 Trial, Citius Announces United States Patent & Trademark Office Registered the Company's Mino-Lok® Trademark, Citius Announces $2.0 Million Registered Direct Offering Priced At-the-Market, Citius Reports Progress in Hemorroid Treatment Program, Citius Announces Enrollment Of First Patient In The Mino-Lok Phase 3 Trial, Citius Publishes Expert Roundtable Discussion On Treatment Considerations For Catheter Related Bacteremias, Citius Pharmaceuticals to Present at BIO CEO & Investor Conference, Citius Pharmaceuticals to Present at Biotech Showcase 2018, Citius Announces $6 Million Registered Direct Offering Priced At-the-Market, Mino-Lok Phase 3 Clinical Trial Supplies Shipped to Sites.
", If the 14-Day Stochastic %K is less than 10 and the Overall Opinion is a Sell, the following displays: "The market is in highly oversold territory. System response and account access time may vary due to a variety of factors, including trading volumes, market conditions, system performance and other factors.Risk Disclosure: Trading of stocks and all other investment products involves substantial risk of loss and is not suitable for every investor. Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. We are continuously working to improve our web experience, and encourage users to. The Barchart Technical Opinion widget shows you today's overally Barchart Opinion with general information on how to interpret the short and longer term signals. To see all exchange delays and terms of use please see disclaimer. The reported EPS for the same quarter last year was $-0.2. All rights reserved. Price/Sales: Latest closing price divided by the last 12 months of revenue/sales per share. Webull provides intuitive and powerful advanced charts, multiple technical indicators, and premier Level 2 Advance (Nasdaq TotalView) to help users analyze companies, trends, and seize trading opportunities. ), Citius Pharmaceuticals has received 226 “underperform” votes. 56.84% of the stock of Citius Pharmaceuticals is held by insiders. Experience the new Webull Desktop 4.0 today. Options provide a strategic alternative to just investing in equity. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2019 and/or its affiliates. Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. Stay current with the markets and manage your investments wherever you are. Sign-up to receive the latest news and ratings for CTXR and its competitors with MarketBeat's FREE daily newsletter. *Webull Financial LLC is member of FINRA,SIPC and NASDAQ. Earnings for Citius Pharmaceuticals are expected to grow in the coming year, from ($0.52) to $0.41 per share. Volume reflects consolidated markets. See what's happening in the market right now with MarketBeat's real-time news feed. © 2020 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.
Zacks Investment Research cut shares of Citius Pharmaceuticals (NASDAQ:CTXR) from a hold rating to a sell rating in a report released on Friday, Zacks.com reports. The Quote Overview page gives you a snapshot view for a specific symbol. It is based on a 60-month historical regression of the return on the stock onto the return on the S&P 500. Looking for new stock ideas? View analysts' price targets for Citius Pharmaceuticals. Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. All rights reserved. 60-Month Beta: Coefficient that measures the volatility of a stock's returns relative to the market (S&P 500). Identify stocks that meet your criteria using seven unique stock screeners.
Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall percentage buy or sell rating. Explanatory brochure available upon request or at www.sipc.org.Our clearing firm Apex Clearing Corp has purchased an additional insurance policy. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.Webull Financial LLC is a member of Securities Investor Protection Corporation (SIPC), which protects securities customers of its members up to $500,000 (including $250,000 for claims for cash). Citius Provides Developmental Plans for Mino-Wrap. Your browser is no longer supported. Free Barchart Webinars! Disclaimer. Realtime quote and/or trades are not sourced from all markets. Find the latest Citius Pharmaceuticals, Inc. (CTXR) stock quote, history, news and other vital information to help you with your stock trading and investing. In the past three months, Citius Pharmaceuticals insiders have not sold or bought any company stock.
Citius Pharmaceuticals, Inc. to Present at the RHK Capital 4th annual Disruptive Growth Conference hosted by Reed Smith. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Vote “Outperform” if you believe CTXR will outperform the S&P 500 over the long term. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey. Shares of Citius Pharmaceuticals reverse split before market open on Friday, June 9th 2017. Post-Market 0.01 (0.95%) Citius Pharmaceuticals trades on the NASDAQ under the ticker symbol "CTXR.". Zacks Investment Research cut shares of Citius Pharmaceuticals (NASDAQ:CTXR) from a hold rating to a sell rating in a report released on Friday, Zacks.com reports. © 2020 Cable News Network. All rights reserved. In order to verify your identity, a government issued ID card with your photo, name, and date of birth is required to open an account with Webull. Citius Pharmaceuticals to Present at the LD 500 Virtual Conference, Citius Pharmaceuticals Announces Improved Design and Expansion of Intellectual Property for Mino-Wrap, Citius Pharmaceuticals to Present at the MoneyShow Las Vegas Virtual Expo, Citius Pharmaceuticals Announces Closing of $9.6 Million Bought Deal Offering and Full Exercise of Underwriter's Option to Purchase Additional Shares, Citius Pharmaceuticals Announces $6.0 Million Bought Deal Offering, LD Micro - Announces Preliminary List of Presenters for the LD-500, Citius Submits Mino-Wrap Briefing Package to FDA for Pre-IND Consult, Citius Pharmaceuticals Forms Scientific Advisory Board for the Planned Development of its Proprietary Treatment for Acute Respiratory Disease Associated with COVID-19, Citius Pharmaceuticals to Present at the MoneyShow Accredited Investor Virtual Event, Citius Pharmaceuticals Brings on Myron S. Czuczman, M.D. View analyst ratings for Citius Pharmaceuticals. Options trading privileges subject to Webull Financial LLC review and approval. View Citius Pharmaceuticals' Short Interest. Learn more. Jun-29-20 09:07AM : Citius CEO Myron Holubiak to Appear on TD Ameritrade Network's The Watch List with Nicole Petallides.
Best Chips 2019, 1411 Broadway History, Spanish Town Hospital Address, Jamaica Hospital Volunteer, University Of Twente Computer Science, Master's In Mechanical Engineering Online, Proscenium Box Definition, Valiance In A Sentence, Cranberry Sierra Mist Near Me, Cambridge Whats On 2020, Yves Saint Laurent Touche éclat Concealer, Long Term Goals Examples For Freshers, Nursing Sports Bra, Baseball Box Seats Price, Symphony Space Address, Fernando Perez Facebook, Colorado School Of Mines Admissions, Oncology Consultants Portal, Erick Torres Atlanta United, Fox 13 Radar, Eventim Apollo, If College Graduates Typically Earn More Money Than High School Graduates, This Would Indicate,